These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10382974)

  • 21. The Saudi Diabetic Kidney Disease study (Saudi-DKD): clinical characteristics and biochemical parameters.
    Al-Rubeaan K; Siddiqui K; Alghonaim M; Youssef AM; AlNaqeb D
    Ann Saudi Med; 2018; 38(1):46-56. PubMed ID: 29295969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diabetic nephropathy. Is end-stage renal disease inevitable?
    Bogusky RT
    Postgrad Med; 1983 Oct; 74(4):339-49. PubMed ID: 6353391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal replacement therapy in patients with diabetic nephropathy, 1980-1985. Report from the European Dialysis and Transplant Association Registry.
    Brunner FP; Brynger H; Challah S; Fassbinder W; Geerlings W; Selwood NH; Tufveson G; Wing AJ
    Nephrol Dial Transplant; 1988; 3(5):585-95. PubMed ID: 3146713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.
    Jerums G; Panagiotopoulos S; Forbes J; Osicka T; Cooper M
    Arch Biochem Biophys; 2003 Nov; 419(1):55-62. PubMed ID: 14568009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diabetic nephropathy and prevention of diabetic nephropathy caused chronic renal insufficiency].
    Jakić M; Jakić M; Zibar L; Mihaljević D; Stipanić S; Teskera T
    Lijec Vjesn; 2009; 131(7-8):218-25. PubMed ID: 19769285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.
    Bucala R; Makita Z; Vega G; Grundy S; Koschinsky T; Cerami A; Vlassara H
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9441-5. PubMed ID: 7937786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diabetes mellitus and dialysis.
    Stein G; Fünfstück R; Schiel R
    Minerva Urol Nefrol; 2004 Sep; 56(3):289-303. PubMed ID: 15467507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced glycosylation end products in diabetic renal and vascular disease.
    Bucala R; Vlassara H
    Am J Kidney Dis; 1995 Dec; 26(6):875-88. PubMed ID: 7503061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renoprotective effects of a novel inhibitor of advanced glycation.
    Forbes JM; Soulis T; Thallas V; Panagiotopoulos S; Long DM; Vasan S; Wagle D; Jerums G; Cooper ME
    Diabetologia; 2001 Jan; 44(1):108-14. PubMed ID: 11206401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
    Sourris KC; Forbes JM
    Curr Drug Targets; 2009 Jan; 10(1):42-50. PubMed ID: 19149535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
    Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
    Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes-related end-stage renal disease in Austria 1965-2013.
    Prischl FC; Auinger M; Säemann M; Mayer G; Rosenkranz AR; Wallner M; Kramar R;
    Nephrol Dial Transplant; 2015 Nov; 30(11):1920-7. PubMed ID: 25977308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in diabetic nephropathy.
    Marshall SM
    Postgrad Med J; 2004 Nov; 80(949):624-33. PubMed ID: 15537844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
    Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
    Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease.
    Bierhaus A; Ritz E; Nawroth PP
    Nephrol Dial Transplant; 1996; 11 Suppl 5():87-90. PubMed ID: 9044315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible significance of advanced glycation end products in serum in end-stage renal disease and in late complications of diabetes.
    Dolhofer-Bliesener R; Lechner B; Gerbitz KD
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):355-61. PubMed ID: 8704053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN).
    Yuan Y; Sun H; Sun Z
    Lipids Health Dis; 2017 Jun; 16(1):126. PubMed ID: 28659153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.